Catalent (CTLT)
(Delayed Data from NYSE)
$60.59 USD
-0.12 (-0.20%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $60.58 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$60.59 USD
-0.12 (-0.20%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $60.58 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth A Momentum A VGM
Zacks News
Vaxart (VXRT) Surges: Stock Moves 8.1% Higher
by Zacks Equity Research
Vaxart (VXRT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Champions Oncology (CSBR) Catches Eye: Stock Jumps 9.2%
by Zacks Equity Research
Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Etsy, Generac, Catalent, Fortune Brands Home & Security and Wayfair
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Etsy, Generac, Catalent, Fortune Brands Home & Security and Wayfair
Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
6 Top Stocks That Turned Large Cap From Mid Cap Amid Pandemic
by Nalak Das
In the due course of the S&P 400 Index's fabulous performance in the past five months, several mid-cap stocks have become large caps. We have selected six of these that carry a favorable Zacks Rank.
New Strong Buy Stocks For September 11th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer
by Zacks Equity Research
Exelixis (EXEL) signs a collaboration agreement with private biotech NBE-Therapeutics for developing novel antibody-drug conjugates (ADCS) to address cancer. It also inks a similar deal with Catalent.
Merck Announces Detailed Data on Late-Stage Cough Candidate
by Zacks Equity Research
Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.
Radius Completes Enrollment in Phase III Osteoporosis Study
by Zacks Equity Research
Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Is Catalent (CTLT) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
Is Catalent (CTLT) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
High-Flying Equities Stumble, but Remain Near All-Time Highs
by David Borun
Technology stocks slip modestly as investors reassess valuations after an historic rally off March lows.
Company News for Sep1, 2020
by Zacks Equity Research
Companies In The News Are: CTLT, TSLA, AIMT, AMZN.
Catalent (CTLT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 0.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y
by Zacks Equity Research
Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors focus is likely to be on the progress of its pipeline candidates, especially coronavirus vaccine candidate, on the second-quarter earrings call.
Moderna Collaborates to Support Coronavirus Vaccine Supply
by Zacks Equity Research
Moderna (MRNA) signs manufacturing deal with Europe-based pharma company, Rovi, to support supply of its coronavirus vaccine in ex-US markets.
Moderna Completes Enrollment in Phase II Coronavirus Study
by Zacks Equity Research
Moderna (MRNA) is progressing well with its coronavirus vaccine development. It completes enrollment in a phase II study and finalizes phase III study protocol.
Moderna Collaborates With Catalent for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Catalent (CTLT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 2.04% and 10.18%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
PCRX or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PCRX vs. CTLT: Which Stock Is the Better Value Option?